Transition from Intravenous Immunoglobulin to Efgartigimod PH20 SC in Participants with Chronic Inflammatory Demyelinating Polyneuropathy: A Phase 4 Study in Progress (P10-11.026)
To assess the successful and safe transition to subcutaneous (SC) efgartigimod PH20 (co-formulated with recombinant human hyaluronidase PH20) treatment 1 week after last intravenous immunoglobulin (IVIg) infusion in adults with chronic inflammatory demyelinating polyneuropathy (CIDP).
Authors
- Arne De Roeck (ORCID: https://orcid.org/0000-0001-5155-0289)
- Jon Beauchamp
- Jeffrey T. Guptill (ORCID: https://orcid.org/0000-0002-0312-0716)
- Geoffrey Istas (ORCID: https://orcid.org/0000-0002-7027-5611)
- Katerina Anokhina (ORCID: https://orcid.org/0000-0002-8257-1151)
- Benjamin Van Hoorick
- Anneleen Remmerie (ORCID: https://orcid.org/0000-0001-5433-2316)
- Erik Hofman
- Yessar Hussain
Institutions
- Argenx (Belgium) (BE)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211925
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00